CODEX Relapsed and Refractory Multiple Myeloma (RRMM) Database Fact Sheet CODEX Relapsed and Refractory Multiple Myeloma (RRMM) Database Danielle Pillsbury2025 年 2 月 19 日
Investigator’s Brochure Writing: 5 Tips to Streamline Your SOC Blog Investigator’s Brochure Writing: 5 Tips to Streamline Your SOC Streamline developing a summary of changes for an Investigator’s Brochure, a document that summarizes the…Jim Gallagher2025 年 2 月 19 日
How to Modernize Patient Narrative Writing On-Demand Webinar 如何使患者叙事撰写现代化 Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…Danielle Pillsbury2025 年 2 月 12 日
Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling Video Certara Phoenix 平台 — 全球最值得信赖的药代动力学/药效学(PK/PD)分析与建模平台 Today's drug candidates are more complex than ever. But with development decisions on the line,…Danielle Pillsbury2025 年 2 月 12 日
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies Publication 针对复发难治性(R/R)骨髓纤维化(MF)及其他髓系或实体瘤恶性肿瘤患者的 Navtemadlin 群体药代动力学与药效学分析 This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…Danielle Pillsbury2025 年 2 月 6 日
Best Practices for International Pharma Content Roll-Out Blog 国际医药内容推广的最佳实践 2025 年 1 月 31 日 Pharmaceutical market access, sales, and field teams rely on high-quality, effective content…Danielle Pillsbury2025 年 1 月 31 日
Transforming Perspectives: 25 Years of PBPK Modeling in Drug-Drug Interactions On-Demand Webinar 转变视角:药物相互作用 PBPK 建模 25 年 Vice President and Head of Global PK/PD and Pharmacometrics at Eli Lilly and Company Dr.…Danielle Pillsbury2025 年 1 月 29 日
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA) On-Demand Webinar 利用基于模型的荟萃分析 (MBMA) 解决药物开发难题 In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…Danielle Pillsbury2025 年 1 月 9 日
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease Publication INTERCEPT-AD:一项针对阿尔茨海默病所致轻度认知障碍或轻度痴呆患者的静脉注射 Sabirnetug 的 I 期研究 The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…Danielle Pillsbury2025 年 1 月 8 日
Where to Start? Setting Your Medical Writing Team Up for Success with GenAI On-Demand Webinar 从何入手?利用 GenAI 让您的医学撰写团队取得成功 Generative AI (GenAI) is poised to revolutionize writing and report generation. In fact, industry studies…Danielle Pillsbury2025 年 1 月 6 日